Keicht drug thread 2

Sachlichkeit

Sachlichkeit

blogposting
Joined
May 11, 2025
Posts
354
Reputation
345
No gatekeeping

In minecraft

follow up of: https://looksmax.org/threads/esoteric-framecel-heightcel-drug-thread.1502129/

Relevant growth related pathways
GH/IGF1 Axis (growth hormone) Stimulator
TGF Beta. similar to myostatin/follistatin muscle cap but de
als with bones as well. Sclupts & stops growth. Regulator
WNT/B cantenin
. Stimulator
FGFR
. Regulator
ESTROGEN.
Not a growth pathway but probably the most important thing to manage when comes to longitudinal growth as it is the major reason growth plates ossify and longitudinal growth stops

These pathways are dictated by genetic expression

Most important pathway is GH/IGF1.

GH/IGF High dose exogenous HGH (8-10) IU/day combined with high protein diet consisting of full amino acid profile. Whey works. 1-1.5g/lb.

TGFB pirfenidone & losartan. Pirfenidone is an anti fibrotic medication used to treat tissue scarring. Short half life. Needs to be dosed 3x/day 600mg per dose. There isn't really any effective affordable way of downregulating TGFB. Losartan & Pirfenidone are the best bet.

WNTB cantenin. KY19382 either injected subcutaneously at 0.25mg pharmaceutical grade or ~0.80mg raw powder ingested orally. see, Literal heightpills 2. ROMOSOZUMAB, Medically approved WNT/B cantenin pathway modulator. 210MG/ injection every month. Carcinogenic, has a maximum of 2 years lifetime use. Will post about it in thread later. KY19832 has better prospects for height gain because of how it targets WNTB, Romo will just make you wide. Easy to source, doesn't decay while being shipped. Kind of expensive ~$400usd/mo

FGFR. Infigratinib. Universally targets FGFR which targets FGFR 3, A mutation of Fibroblast growth factor 3 is what causes dwarfism so inhibition of it allows for normal growth. See, literal heightpills. Pan FGFR inhibition can cause significant vision issues. low dose, not using it chronically, temporarily inhibiting FGFR during the beginning of cycles to kickstart osteoblast proliferation (growing bones) with less resistance from FGFR.

ESTROGEN. If growth plates are open, estrogen will close them. There are a myriad of signals the body can produce that tell growth plates to close but if there is no estrogen the growth plates will not close. Letrozole is the medical gold standard for keeping growth plates open. I mentioned before in an older thread that estrogen is an anti resorptive. It prevents the breaking down of bone. Its crucial for libido, bone health, joint health, brain health, mood regulation. Insane and retarded. So we can't completely eradicate it, it is simply not worth the height gain if any. Raloxifene is a SERM synthetic estrogen modulator that mimics estrogens effects but seems to have negligible effects on growth plates. If that works, it will be the standard for vertical growth as the primary drawback from the use of aromatase inhibitors is how crucial estrogen is for normal function.

High dose androgens during development for male dimorphism

Testosterone has a 1:1 androgenic to anabolic ratio. Anabolism deals with muscle growth, Androgenics deal with dimorphism. Things like fat redistribution, facial hair, even the hooding of eyebrows(I think), secondary sexual characteristics, masculine growth (skeletal V-taper,) deepening of voice, and so on and so forth.

Androgens work synergistically with HGH for growth. Both stimulate osteoblast proliferation, Gear increases height velocity, increase in bone mineral density.

Growth is, low androgens >>> GH starts increasing, sustained linear growth >>> then puberty, high androgens, high GH, Height velocity increases, grow bigger faster >>> tail end of growth, GH decreases, androgens increase, estrogen feedback closes growth plates

Suppress estrogen to abnormal levels while keeping GH and androgens at supraphysiological levels and you will have supraphysiological growth (assuming you are not too old, 13-24, 13-22 whatever)

Trenbolone enanthate & testosterone enanthate

Tren is a non aromatizing steroid originally intended for cattle with a 5:5 androgenic anabolic ratio.
has a harsh side effect profile making it unfit for medical use.

So why use it? It lowers protein requirement for growth and doesn't aromatize which means you don't need to use as much aromatase inhibitors. If you wanted something like the benefits of a gram of test a week without the gram equivalent of DHT you could cut it with 500 test 100 tren which would produce similar results with less hairloss risk.

Testosterone enanthate is just basic primary male sex hormone complete with downstream hormonal profile. DHT is a downstream of Testosterone at a maybe (20%) conversion rate that drives dimorphism MORE than testosterone dose with a 5:0 Androgenic to anabolic ratio. It is the primary cause of hairloss in men.

Testosterone is the best steroid because of the downstream profile. Your brain will develop differently, you will think differently if you are on man made steroid derivative. Enanthate is the ester that extends the half life of the androgen in your body. Injections should be every 4-5 days.

Rest of steroids have their place but we dont care

Androgen ancillaries

Losartan/Telmisartan (blood pressure v important)
GHK CU (skin)
AI's (estrogen management)
Dutasteride/finasteride Hairloss, + skin protection from supraphysiological DHT levels
Topical RU58841, for hairloss. Anti androgen that will prevent hairloss from any androgen
Blood pressure cuff for blood pressure obv
HCG to maintain testicular function. Infertility from steroids is largely cope. HMG is more effective than HCG if you are worried.

Dimorphism is about bones, not muscle. How do we drive a pro osteogenic environment?

1. Prevent resorption using DHT & Estrogen or a synthetic estrogen like raloxifene, Anti resorption drugs like Alendronate
2. HGH & androgens
3. Mechanical tension, exercise
4. diet > High protein, full amino acid profile to fully utilize HGH dosages, Vitamin K2 MK7, Zinc, Calcium, Vit D, & Magnesium

BONE DRUGS

PTH analogs abaloparatide and teriparatide.


Parathyroid hormone analogs cause bone resorption (the breaking down of bones) but then stimulate osteoblast proliferation that outweighs the resorption resulting in a net gain of bone.

Teriparatide is the worse, more risky of the two and should only be used if you have an adverse reaction to abaloparatide. Like romosozumab, these are carcinogenic and have a maximum lifetime use of 2 years. The body will begin to break down the bone built by PTH analogs after treatment so use an anti resorptive drug like alendronate for a literal year.

ANTI RESORPTION

Is severely underrated in bone growth as androgens don't preserve bone, they build it. Raloxifene, estrogen, (DHT, is unique in that sense because it has been shown to retain bone mineral density in the absence of both estrogen in testosterone,) and the Bisphosphonate Alendronate. Preventing resorption means more of our androgen GH gains will go towards accruing mass rather than fighting against the breakdown.

ROMOSOZUMAB

Is the most effective bone drug for thickening/widening. It should be used (if at all) after you reach your desired height because its much better at making you wider, not so much taller. PTH analogs are better for making you taller. Carcinogenic, 2 year lifetime use, Yes it is more effective than PTH analogs

TETRANALOGS/MMP INHIBITORS

THREAD. MMP'S break down collagen scaffolding, Inflammation via gear upregulates them. Low dose MMP inhibitors Doxycycline and minocycline prevent this resulting in more bone gains

HOLY GRAIL OGRE GENE DRUGS

remember, These pathways are dictated by genetic expression.

So instead of individually trying to downregulate or upregulate them, why not just alter the gene expression? Obv this is riskiest, epigenetic permanent effects. WE BALL

Vorinostat enjoyers

3 relevant gene drugs available on open market

1. HDAC inhibitor Vorinostat
2. EZH2 inhibitor Tazmetostat
3. DNMT inhibitor azacitidine & oral azacitidine Onureg

Vorinostat
enhances gene transcription. Allows for more genetic expression, indiscriminately. People pair it with androgens to enhance their masculinizing effect. Think of vorinostat as a megaphone. Though because it universally allows for more genetic expression its not just used for androgens. Chronic use is bad for bones, bad for growth, not to mention ur genes being "unlocked" for long period of time thats obviously not good. I would recommend you cycle it but its anti osteogenic effects on bones and such I think is just being drastically outperformed by the amount of gear these people are blasting and thats how they get away with it.

"Though because it universally allows for more genetic expression its not just used for androgens"

Cognitive Improvement by Vorinostat through Modulation of Endoplasmic Reticulum Stress in a Corticosterone-Induced Chronic Stress Model in Mice
Upregulation of HDAC9 in hippocampal neurons mediates depression-like behaviours (eg. Anhedonia) by inhibiting ANXA2 degradation

Vorinostat (SAHA) May Exert Its Antidepressant-Like Effects Through the Modulation of Oxidative Stress Pathways
Vorinostat Corrects Cognitive and Non-Cognitive Symptoms in a Mouse Model of Fragile X Syndrome
The histone deacetylase inhibitor Vorinostat (SAHA ) alleviates depression-like behavior and normalizes epigenetic changes in the hippocampus during ethanol withdrawal
Early-life stress-induced visceral hypersensitivity and anxiety behavior is reversed by histone deacetylase inhibition (Vorinostat).
Suberoylanilide hydroxamic acid attenuates cognitive impairment in offspring caused by maternal surgery during mid-pregnancy
(Vorinostat) SAHA Improves Depressive Symptoms, Cognitive Impairment and Oxidative Stress: Rise of a New Antidepressant Class

TAZMETOSTAT
removes the epigenetic brake on growth genes present during puberty. That re-exposes the programs that let GH and androgens drive growth and masculinization. In adulthood, EZH2 shuts these genes down, the body genetically shifts into maintenance mode instead of growth. So basically, we turn the programs on, blast androgens, BOOM, second puberty. Whereas vstat will exaggerate this growth.

Taz is generally well tolerated, easier to source, and less risky and more specific than vorinostat though they serve two different purposes. There are some drugs that are just better made than others and taz is one of them.

DNMTI azacitidine & oral azacitidine Onureg

stronger more broad version of tazmetosat. Activates PRE PUBERTY growth programs (such as IGF2 natal version of IGF1 which shuts down in puberty forever.) Obviously the ramifications of genetically resensitizing your body to growth on a childhood/fetal level isn't as promising as it is daunting and risky.

Tazmetostat, selective re-activation of pubertal genes >>>> gene signaling for second partial puberty
Onureg, broad and indiscriminate re-activation of core developmental genes

Making vorinostat bioavailable (will need to source raw powder)
Tazmetostat bottles are already formulated, expensive but feasible for the employed.
Onureg oral version of DNTMI azacitidine probably mega expensive IDK. Aza can be pinned subcutaneously, its cheap and easy to source.

SO

If in puberty & want to "ogremaxx" HDACI

Re-run pubertal programs, Taz

Retarded? Azacitidine

GENE PCT. Post cycle to close genes and reduce genetic damage

SAMe
Methyl-B12
Methyl-Folate
Choline
Creatine

These are all supplements.

Thats all for now, good luck.

1758423426392
 
Last edited:
  • +1
  • Love it
Reactions: 7evenvox22, gigacumster3000, Mike456 and 3 others
will running romosozumab before reaching desired height hinder reaching goal height. And can i run my vorinostat and tazemetostat at same time?
 
No gatekeeping

In minecraft

follow up of: https://looksmax.org/threads/esoteric-framecel-heightcel-drug-thread.1502129/

Relevant growth related pathways
GH/IGF1 Axis (growth hormone) Stimulator
TGF Beta. similar to myostatin/follistatin muscle cap but de
als with bones as well. Sclupts & stops growth. Regulator
WNT/B cantenin
. Stimulator
FGFR
. Regulator
ESTROGEN.
Not a growth pathway but probably the most important thing to manage when comes to longitudinal growth as it is the major reason growth plates ossify and longitudinal growth stops

These pathways are dictated by genetic expression

Most important pathway is GH/IGF1.

GH/IGF High dose exogenous HGH (8-10) IU/day combined with high protein diet consisting of full amino acid profile. Whey works. 1-1.5g/lb.

TGFB pirfenidone & losartan. Pirfenidone is an anti fibrotic medication used to treat tissue scarring. Short half life. Needs to be dosed 3x/day 600mg per dose. There isn't really any effective affordable way of downregulating TGFB. Losartan & Pirfenidone are the best bet.

WNTB cantenin. KY19382 either injected subcutaneously at 0.25mg pharmaceutical grade or ~0.80mg raw powder ingested orally. see, Literal heightpills 2. ROMOSOZUMAB, Medically approved WNT/B cantenin pathway modulator. 210MG/ injection every month. Carcinogenic, has a maximum of 2 years lifetime use. Will post about it in thread later. KY19832 has better prospects for height gain because of how it targets WNTB, Romo will just make you wide. Easy to source, doesn't decay while being shipped. Kind of expensive ~$400usd/mo

FGFR. Infigratinib. Universally targets FGFR which targets FGFR 3, A mutation of Fibroblast growth factor 3 is what causes dwarfism so inhibition of it allows for normal growth. See, literal heightpills. Pan FGFR inhibition can cause significant vision issues. low dose, not using it chronically, temporarily inhibiting FGFR during the beginning of cycles to kickstart osteoblast proliferation (growing bones) with less resistance from FGFR.

ESTROGEN. If growth plates are open, estrogen will close them. There are a myriad of signals the body can produce that tell growth plates to close but if there is no estrogen the growth plates will not close. Letrozole is the medical gold standard for keeping growth plates open. I mentioned before in an older thread that estrogen is an anti resorptive. It prevents the breaking down of bone. Its crucial for libido, bone health, joint health, brain health, mood regulation. Insane and retarded. So we can't completely eradicate it, it is simply not worth the height gain if any. Raloxifene is a SERM synthetic estrogen modulator that mimics estrogens effects but seems to have negligible effects on growth plates. If that works, it will be the standard for vertical growth as the primary drawback from the use of aromatase inhibitors is how crucial estrogen is for normal function.

High dose androgens during development for male dimorphism

Testosterone has a 1:1 androgenic to anabolic ratio. Anabolism deals with muscle growth, Androgenics deal with dimorphism. Things like fat redistribution, facial hair, even the hooding of eyebrows(I think), secondary sexual characteristics, masculine growth (skeletal V-taper,) deepening of voice, and so on and so forth.

Androgens work synergistically with HGH for growth. Both stimulate osteoblast proliferation, Gear increases height velocity, increase in bone mineral density.

Growth is, low androgens >>> GH starts increasing, sustained linear growth >>> then puberty, high androgens, high GH, Height velocity increases, grow bigger faster >>> tail end of growth, GH decreases, androgens increase, estrogen feedback closes growth plates

Suppress estrogen to abnormal levels while keeping GH and androgens at supraphysiological levels and you will have supraphysiological growth (assuming you are not too old, 13-24, 13-22 whatever)

Trenbolone enanthate & testosterone enanthate

Tren is a non aromatizing steroid originally intended for cattle with a 5:5 androgenic anabolic ratio.
has a harsh side effect profile making it unfit for medical use.

So why use it? It lowers protein requirement for growth and doesn't aromatize which means you don't need to use as much aromatase inhibitors. If you wanted something like the benefits of a gram of test a week without the gram equivalent of DHT you could cut it with 500 test 100 tren which would produce similar results with less hairloss risk.

Testosterone enanthate is just basic primary male sex hormone complete with downstream hormonal profile. DHT is a downstream of Testosterone at a maybe (20%) conversion rate that drives dimorphism MORE than testosterone dose with a 5:0 Androgenic to anabolic ratio. It is the primary cause of hairloss in men.

Testosterone is the best steroid because of the downstream profile. Your brain will develop differently, you will think differently if you are on man made steroid derivative. Enanthate is the ester that extends the half life of the androgen in your body. Injections should be every 4-5 days.

Rest of steroids have their place but we dont care

Androgen ancillaries

Losartan/Telmisartan (blood pressure v important)
GHK CU (skin)
AI's (estrogen management)
Dutasteride/finasteride Hairloss, + skin protection from supraphysiological DHT levels
Topical RU58841, for hairloss. Anti androgen that will prevent hairloss from any androgen
Blood pressure cuff for blood pressure obv
HCG to maintain testicular function. Infertility from steroids is largely cope. HMG is more effective than HCG if you are worried.

Dimorphism is about bones, not muscle. How do we drive a pro osteogenic environment?

1. Prevent resorption using DHT & Estrogen or a synthetic estrogen like raloxifene, Anti resorption drugs like Alendronate
2. HGH & androgens
3. Mechanical tension, exercise
4. diet > High protein, full amino acid profile to fully utilize HGH dosages, Vitamin K2 MK7, Zinc, Calcium, Vit D, & Magnesium

BONE DRUGS

PTH analogs abaloparatide and teriparatide.


Parathyroid hormone analogs cause bone resorption (the breaking down of bones) but then stimulate osteoblast proliferation that outweighs the resorption resulting in a net gain of bone.

Teriparatide is the worse, more risky of the two and should only be used if you have an adverse reaction to abaloparatide. Like romosozumab, these are carcinogenic and have a maximum lifetime use of 2 years. The body will begin to break down the bone built by PTH analogs after treatment so use an anti resorptive drug like alendronate for a literal year.

ANTI RESORPTION

Is severely underrated in bone growth as androgens don't preserve bone, they build it. Raloxifene, estrogen, (DHT, is unique in that sense because it has been shown to retain bone mineral density in the absence of both estrogen in testosterone,) and the Bisphosphonate Alendronate. Preventing resorption means more of our androgen GH gains will go towards accruing mass rather than fighting against the breakdown.

ROMOSOZUMAB

Is the most effective bone drug for thickening/widening. It should be used (if at all) after you reach your desired height because its much better at making you wider, not so much taller. PTH analogs are better for making you taller. Carcinogenic, 2 year lifetime use, Yes it is more effective than PTH analogs

TETRANALOGS/MMP INHIBITORS

THREAD. MMP'S break down collagen scaffolding, Inflammation via gear upregulates them. Low dose MMP inhibitors Doxycycline and minocycline prevent this resulting in more bone gains

HOLY GRAIL OGRE GENE DRUGS

remember, These pathways are dictated by genetic expression.

So instead of individually trying to downregulate or upregulate them, why not just alter the gene expression? Obv this is riskiest, epigenetic permanent effects. WE BALL

Vorinostat enjoyers

3 relevant gene drugs available on open market

1. HDAC inhibitor Vorinostat
2. EZH2 inhibitor Tazmetostat
3. DNMT inhibitor azacitidine & oral azacitidine Onureg

Vorinostat
enhances gene transcription. Allows for more genetic expression, indiscriminately. People pair it with androgens to enhance their masculinizing effect. Think of vorinostat as a megaphone. Though because it universally allows for more genetic expression its not just used for androgens. Chronic use is bad for bones, bad for growth, not to mention ur genes being "unlocked" for long period of time thats obviously not good. I would recommend you cycle it but its anti osteogenic effects on bones and such I think is just being drastically outperformed by the amount of gear these people are blasting and thats how they get away with it.

"Though because it universally allows for more genetic expression its not just used for androgens"

Cognitive Improvement by Vorinostat through Modulation of Endoplasmic Reticulum Stress in a Corticosterone-Induced Chronic Stress Model in Mice
Upregulation of HDAC9 in hippocampal neurons mediates depression-like behaviours (eg. Anhedonia) by inhibiting ANXA2 degradation

Vorinostat (SAHA) May Exert Its Antidepressant-Like Effects Through the Modulation of Oxidative Stress Pathways
Vorinostat Corrects Cognitive and Non-Cognitive Symptoms in a Mouse Model of Fragile X Syndrome
The histone deacetylase inhibitor Vorinostat (SAHA ) alleviates depression-like behavior and normalizes epigenetic changes in the hippocampus during ethanol withdrawal
Early-life stress-induced visceral hypersensitivity and anxiety behavior is reversed by histone deacetylase inhibition (Vorinostat).
Suberoylanilide hydroxamic acid attenuates cognitive impairment in offspring caused by maternal surgery during mid-pregnancy
(Vorinostat) SAHA Improves Depressive Symptoms, Cognitive Impairment and Oxidative Stress: Rise of a New Antidepressant Class

TAZMETOSTAT
removes the epigenetic brake on growth genes present during puberty. That re-exposes the programs that let GH and androgens drive growth and masculinization. In adulthood, EZH2 shuts these genes down, the body genetically shifts into maintenance mode instead of growth. So basically, we turn the programs on, blast androgens, BOOM, second puberty. Whereas vstat will exaggerate this growth.

Taz is generally well tolerated, easier to source, and less risky and more specific than vorinostat though they serve two different purposes. There are some drugs that are just better made than others and taz is one of them.

DNMTI azacitidine & oral azacitidine Onureg

stronger more broad version of tazmetosat. Activates PRE PUBERTY growth programs (such as IGF2 natal version of IGF1 which shuts down in puberty forever.) Obviously the ramifications of genetically resensitizing your body to growth on a childhood/fetal level isn't as promising as it is daunting and risky.

Tazmetostat, selective re-activation of pubertal genes >>>> gene signaling for second partial puberty
Onureg, broad and indiscriminate re-activation of core developmental genes

Making vorinostat bioavailable (will need to source raw powder)
Tazmetostat bottles are already formulated, expensive but feasible for the employed.
Onureg oral version of DNTMI azacitidine probably mega expensive IDK. Aza can be pinned subcutaneously, its cheap and easy to source.

SO

If in puberty & want to "ogremaxx" HDACI

Re-run pubertal programs, Taz

Retarded? Azacitidine

GENE PCT. Post cycle to close genes and reduce genetic damage

SAMe
Methyl-B12
Methyl-Folate
Choline
Creatine

These are all supplements.

Thats all for now, good luck.

View attachment 4131629
Mirin the thread; the real question here though is how many people are actually gonna hop on even one of these :lul:
 
  • +1
Reactions: Mike456 and liyurcc
Mirin the thread; the real question here though is how many people are actually gonna hop on even one of these :lul:
Me right now I’m on half of it
 
  • +1
Reactions: hamiwts
No gatekeeping

In minecraft

follow up of: https://looksmax.org/threads/esoteric-framecel-heightcel-drug-thread.1502129/

Relevant growth related pathways
GH/IGF1 Axis (growth hormone) Stimulator
TGF Beta. similar to myostatin/follistatin muscle cap but de
als with bones as well. Sclupts & stops growth. Regulator
WNT/B cantenin
. Stimulator
FGFR
. Regulator
ESTROGEN.
Not a growth pathway but probably the most important thing to manage when comes to longitudinal growth as it is the major reason growth plates ossify and longitudinal growth stops

These pathways are dictated by genetic expression

Most important pathway is GH/IGF1.

GH/IGF High dose exogenous HGH (8-10) IU/day combined with high protein diet consisting of full amino acid profile. Whey works. 1-1.5g/lb.

TGFB pirfenidone & losartan. Pirfenidone is an anti fibrotic medication used to treat tissue scarring. Short half life. Needs to be dosed 3x/day 600mg per dose. There isn't really any effective affordable way of downregulating TGFB. Losartan & Pirfenidone are the best bet.

WNTB cantenin. KY19382 either injected subcutaneously at 0.25mg pharmaceutical grade or ~0.80mg raw powder ingested orally. see, Literal heightpills 2. ROMOSOZUMAB, Medically approved WNT/B cantenin pathway modulator. 210MG/ injection every month. Carcinogenic, has a maximum of 2 years lifetime use. Will post about it in thread later. KY19832 has better prospects for height gain because of how it targets WNTB, Romo will just make you wide. Easy to source, doesn't decay while being shipped. Kind of expensive ~$400usd/mo

FGFR. Infigratinib. Universally targets FGFR which targets FGFR 3, A mutation of Fibroblast growth factor 3 is what causes dwarfism so inhibition of it allows for normal growth. See, literal heightpills. Pan FGFR inhibition can cause significant vision issues. low dose, not using it chronically, temporarily inhibiting FGFR during the beginning of cycles to kickstart osteoblast proliferation (growing bones) with less resistance from FGFR.

ESTROGEN. If growth plates are open, estrogen will close them. There are a myriad of signals the body can produce that tell growth plates to close but if there is no estrogen the growth plates will not close. Letrozole is the medical gold standard for keeping growth plates open. I mentioned before in an older thread that estrogen is an anti resorptive. It prevents the breaking down of bone. Its crucial for libido, bone health, joint health, brain health, mood regulation. Insane and retarded. So we can't completely eradicate it, it is simply not worth the height gain if any. Raloxifene is a SERM synthetic estrogen modulator that mimics estrogens effects but seems to have negligible effects on growth plates. If that works, it will be the standard for vertical growth as the primary drawback from the use of aromatase inhibitors is how crucial estrogen is for normal function.

High dose androgens during development for male dimorphism

Testosterone has a 1:1 androgenic to anabolic ratio. Anabolism deals with muscle growth, Androgenics deal with dimorphism. Things like fat redistribution, facial hair, even the hooding of eyebrows(I think), secondary sexual characteristics, masculine growth (skeletal V-taper,) deepening of voice, and so on and so forth.

Androgens work synergistically with HGH for growth. Both stimulate osteoblast proliferation, Gear increases height velocity, increase in bone mineral density.

Growth is, low androgens >>> GH starts increasing, sustained linear growth >>> then puberty, high androgens, high GH, Height velocity increases, grow bigger faster >>> tail end of growth, GH decreases, androgens increase, estrogen feedback closes growth plates

Suppress estrogen to abnormal levels while keeping GH and androgens at supraphysiological levels and you will have supraphysiological growth (assuming you are not too old, 13-24, 13-22 whatever)

Trenbolone enanthate & testosterone enanthate

Tren is a non aromatizing steroid originally intended for cattle with a 5:5 androgenic anabolic ratio.
has a harsh side effect profile making it unfit for medical use.

So why use it? It lowers protein requirement for growth and doesn't aromatize which means you don't need to use as much aromatase inhibitors. If you wanted something like the benefits of a gram of test a week without the gram equivalent of DHT you could cut it with 500 test 100 tren which would produce similar results with less hairloss risk.

Testosterone enanthate is just basic primary male sex hormone complete with downstream hormonal profile. DHT is a downstream of Testosterone at a maybe (20%) conversion rate that drives dimorphism MORE than testosterone dose with a 5:0 Androgenic to anabolic ratio. It is the primary cause of hairloss in men.

Testosterone is the best steroid because of the downstream profile. Your brain will develop differently, you will think differently if you are on man made steroid derivative. Enanthate is the ester that extends the half life of the androgen in your body. Injections should be every 4-5 days.

Rest of steroids have their place but we dont care

Androgen ancillaries

Losartan/Telmisartan (blood pressure v important)
GHK CU (skin)
AI's (estrogen management)
Dutasteride/finasteride Hairloss, + skin protection from supraphysiological DHT levels
Topical RU58841, for hairloss. Anti androgen that will prevent hairloss from any androgen
Blood pressure cuff for blood pressure obv
HCG to maintain testicular function. Infertility from steroids is largely cope. HMG is more effective than HCG if you are worried.

Dimorphism is about bones, not muscle. How do we drive a pro osteogenic environment?

1. Prevent resorption using DHT & Estrogen or a synthetic estrogen like raloxifene, Anti resorption drugs like Alendronate
2. HGH & androgens
3. Mechanical tension, exercise
4. diet > High protein, full amino acid profile to fully utilize HGH dosages, Vitamin K2 MK7, Zinc, Calcium, Vit D, & Magnesium

BONE DRUGS

PTH analogs abaloparatide and teriparatide.


Parathyroid hormone analogs cause bone resorption (the breaking down of bones) but then stimulate osteoblast proliferation that outweighs the resorption resulting in a net gain of bone.

Teriparatide is the worse, more risky of the two and should only be used if you have an adverse reaction to abaloparatide. Like romosozumab, these are carcinogenic and have a maximum lifetime use of 2 years. The body will begin to break down the bone built by PTH analogs after treatment so use an anti resorptive drug like alendronate for a literal year.

ANTI RESORPTION

Is severely underrated in bone growth as androgens don't preserve bone, they build it. Raloxifene, estrogen, (DHT, is unique in that sense because it has been shown to retain bone mineral density in the absence of both estrogen in testosterone,) and the Bisphosphonate Alendronate. Preventing resorption means more of our androgen GH gains will go towards accruing mass rather than fighting against the breakdown.

ROMOSOZUMAB

Is the most effective bone drug for thickening/widening. It should be used (if at all) after you reach your desired height because its much better at making you wider, not so much taller. PTH analogs are better for making you taller. Carcinogenic, 2 year lifetime use, Yes it is more effective than PTH analogs

TETRANALOGS/MMP INHIBITORS

THREAD. MMP'S break down collagen scaffolding, Inflammation via gear upregulates them. Low dose MMP inhibitors Doxycycline and minocycline prevent this resulting in more bone gains

HOLY GRAIL OGRE GENE DRUGS

remember, These pathways are dictated by genetic expression.

So instead of individually trying to downregulate or upregulate them, why not just alter the gene expression? Obv this is riskiest, epigenetic permanent effects. WE BALL

Vorinostat enjoyers

3 relevant gene drugs available on open market

1. HDAC inhibitor Vorinostat
2. EZH2 inhibitor Tazmetostat
3. DNMT inhibitor azacitidine & oral azacitidine Onureg

Vorinostat
enhances gene transcription. Allows for more genetic expression, indiscriminately. People pair it with androgens to enhance their masculinizing effect. Think of vorinostat as a megaphone. Though because it universally allows for more genetic expression its not just used for androgens. Chronic use is bad for bones, bad for growth, not to mention ur genes being "unlocked" for long period of time thats obviously not good. I would recommend you cycle it but its anti osteogenic effects on bones and such I think is just being drastically outperformed by the amount of gear these people are blasting and thats how they get away with it.

"Though because it universally allows for more genetic expression its not just used for androgens"

Cognitive Improvement by Vorinostat through Modulation of Endoplasmic Reticulum Stress in a Corticosterone-Induced Chronic Stress Model in Mice
Upregulation of HDAC9 in hippocampal neurons mediates depression-like behaviours (eg. Anhedonia) by inhibiting ANXA2 degradation

Vorinostat (SAHA) May Exert Its Antidepressant-Like Effects Through the Modulation of Oxidative Stress Pathways
Vorinostat Corrects Cognitive and Non-Cognitive Symptoms in a Mouse Model of Fragile X Syndrome
The histone deacetylase inhibitor Vorinostat (SAHA ) alleviates depression-like behavior and normalizes epigenetic changes in the hippocampus during ethanol withdrawal
Early-life stress-induced visceral hypersensitivity and anxiety behavior is reversed by histone deacetylase inhibition (Vorinostat).
Suberoylanilide hydroxamic acid attenuates cognitive impairment in offspring caused by maternal surgery during mid-pregnancy
(Vorinostat) SAHA Improves Depressive Symptoms, Cognitive Impairment and Oxidative Stress: Rise of a New Antidepressant Class

TAZMETOSTAT
removes the epigenetic brake on growth genes present during puberty. That re-exposes the programs that let GH and androgens drive growth and masculinization. In adulthood, EZH2 shuts these genes down, the body genetically shifts into maintenance mode instead of growth. So basically, we turn the programs on, blast androgens, BOOM, second puberty. Whereas vstat will exaggerate this growth.

Taz is generally well tolerated, easier to source, and less risky and more specific than vorinostat though they serve two different purposes. There are some drugs that are just better made than others and taz is one of them.

DNMTI azacitidine & oral azacitidine Onureg

stronger more broad version of tazmetosat. Activates PRE PUBERTY growth programs (such as IGF2 natal version of IGF1 which shuts down in puberty forever.) Obviously the ramifications of genetically resensitizing your body to growth on a childhood/fetal level isn't as promising as it is daunting and risky.

Tazmetostat, selective re-activation of pubertal genes >>>> gene signaling for second partial puberty
Onureg, broad and indiscriminate re-activation of core developmental genes

Making vorinostat bioavailable (will need to source raw powder)
Tazmetostat bottles are already formulated, expensive but feasible for the employed.
Onureg oral version of DNTMI azacitidine probably mega expensive IDK. Aza can be pinned subcutaneously, its cheap and easy to source.

SO

If in puberty & want to "ogremaxx" HDACI

Re-run pubertal programs, Taz

Retarded? Azacitidine

GENE PCT. Post cycle to close genes and reduce genetic damage

SAMe
Methyl-B12
Methyl-Folate
Choline
Creatine

These are all supplements.

Thats all for now, good luck.

View attachment 4131629
Theoretical effects of re activating natal IGF-2 via azacitidine

GH converts to IGF1 which is primary pathway for pubertal/adult growth in human body

2-3x stronger than GH for craniofacial bone remodeling
2x stronger than GH for periosteal bone thickening
negligible for muscle hypertrophy
IGF2 REGULATES facial bone structure development in children. GH does not.

This could theoretically "re-roll" musculature and skeletal structure physique through re structuring the makeup from a top down perspective. The genetic pathway. Because IGF2 regulates growth in such a significant manner, it can SHIFT skeletal and muscular proportions. obv we are blasting androgens it will bias them towards masculine proportioning.

The most obvious should be facial remodeling.
 
  • +1
Reactions: gigacumster3000 and Mike456
No gatekeeping

In minecraft

follow up of: https://looksmax.org/threads/esoteric-framecel-heightcel-drug-thread.1502129/

Relevant growth related pathways
GH/IGF1 Axis (growth hormone) Stimulator
TGF Beta. similar to myostatin/follistatin muscle cap but de
als with bones as well. Sclupts & stops growth. Regulator
WNT/B cantenin
. Stimulator
FGFR
. Regulator
ESTROGEN.
Not a growth pathway but probably the most important thing to manage when comes to longitudinal growth as it is the major reason growth plates ossify and longitudinal growth stops

These pathways are dictated by genetic expression

Most important pathway is GH/IGF1.

GH/IGF High dose exogenous HGH (8-10) IU/day combined with high protein diet consisting of full amino acid profile. Whey works. 1-1.5g/lb.

TGFB pirfenidone & losartan. Pirfenidone is an anti fibrotic medication used to treat tissue scarring. Short half life. Needs to be dosed 3x/day 600mg per dose. There isn't really any effective affordable way of downregulating TGFB. Losartan & Pirfenidone are the best bet.

WNTB cantenin. KY19382 either injected subcutaneously at 0.25mg pharmaceutical grade or ~0.80mg raw powder ingested orally. see, Literal heightpills 2. ROMOSOZUMAB, Medically approved WNT/B cantenin pathway modulator. 210MG/ injection every month. Carcinogenic, has a maximum of 2 years lifetime use. Will post about it in thread later. KY19832 has better prospects for height gain because of how it targets WNTB, Romo will just make you wide. Easy to source, doesn't decay while being shipped. Kind of expensive ~$400usd/mo

FGFR. Infigratinib. Universally targets FGFR which targets FGFR 3, A mutation of Fibroblast growth factor 3 is what causes dwarfism so inhibition of it allows for normal growth. See, literal heightpills. Pan FGFR inhibition can cause significant vision issues. low dose, not using it chronically, temporarily inhibiting FGFR during the beginning of cycles to kickstart osteoblast proliferation (growing bones) with less resistance from FGFR.

ESTROGEN. If growth plates are open, estrogen will close them. There are a myriad of signals the body can produce that tell growth plates to close but if there is no estrogen the growth plates will not close. Letrozole is the medical gold standard for keeping growth plates open. I mentioned before in an older thread that estrogen is an anti resorptive. It prevents the breaking down of bone. Its crucial for libido, bone health, joint health, brain health, mood regulation. Insane and retarded. So we can't completely eradicate it, it is simply not worth the height gain if any. Raloxifene is a SERM synthetic estrogen modulator that mimics estrogens effects but seems to have negligible effects on growth plates. If that works, it will be the standard for vertical growth as the primary drawback from the use of aromatase inhibitors is how crucial estrogen is for normal function.

High dose androgens during development for male dimorphism

Testosterone has a 1:1 androgenic to anabolic ratio. Anabolism deals with muscle growth, Androgenics deal with dimorphism. Things like fat redistribution, facial hair, even the hooding of eyebrows(I think), secondary sexual characteristics, masculine growth (skeletal V-taper,) deepening of voice, and so on and so forth.

Androgens work synergistically with HGH for growth. Both stimulate osteoblast proliferation, Gear increases height velocity, increase in bone mineral density.

Growth is, low androgens >>> GH starts increasing, sustained linear growth >>> then puberty, high androgens, high GH, Height velocity increases, grow bigger faster >>> tail end of growth, GH decreases, androgens increase, estrogen feedback closes growth plates

Suppress estrogen to abnormal levels while keeping GH and androgens at supraphysiological levels and you will have supraphysiological growth (assuming you are not too old, 13-24, 13-22 whatever)

Trenbolone enanthate & testosterone enanthate

Tren is a non aromatizing steroid originally intended for cattle with a 5:5 androgenic anabolic ratio.
has a harsh side effect profile making it unfit for medical use.

So why use it? It lowers protein requirement for growth and doesn't aromatize which means you don't need to use as much aromatase inhibitors. If you wanted something like the benefits of a gram of test a week without the gram equivalent of DHT you could cut it with 500 test 100 tren which would produce similar results with less hairloss risk.

Testosterone enanthate is just basic primary male sex hormone complete with downstream hormonal profile. DHT is a downstream of Testosterone at a maybe (20%) conversion rate that drives dimorphism MORE than testosterone dose with a 5:0 Androgenic to anabolic ratio. It is the primary cause of hairloss in men.

Testosterone is the best steroid because of the downstream profile. Your brain will develop differently, you will think differently if you are on man made steroid derivative. Enanthate is the ester that extends the half life of the androgen in your body. Injections should be every 4-5 days.

Rest of steroids have their place but we dont care

Androgen ancillaries

Losartan/Telmisartan (blood pressure v important)
GHK CU (skin)
AI's (estrogen management)
Dutasteride/finasteride Hairloss, + skin protection from supraphysiological DHT levels
Topical RU58841, for hairloss. Anti androgen that will prevent hairloss from any androgen
Blood pressure cuff for blood pressure obv
HCG to maintain testicular function. Infertility from steroids is largely cope. HMG is more effective than HCG if you are worried.

Dimorphism is about bones, not muscle. How do we drive a pro osteogenic environment?

1. Prevent resorption using DHT & Estrogen or a synthetic estrogen like raloxifene, Anti resorption drugs like Alendronate
2. HGH & androgens
3. Mechanical tension, exercise
4. diet > High protein, full amino acid profile to fully utilize HGH dosages, Vitamin K2 MK7, Zinc, Calcium, Vit D, & Magnesium

BONE DRUGS

PTH analogs abaloparatide and teriparatide.


Parathyroid hormone analogs cause bone resorption (the breaking down of bones) but then stimulate osteoblast proliferation that outweighs the resorption resulting in a net gain of bone.

Teriparatide is the worse, more risky of the two and should only be used if you have an adverse reaction to abaloparatide. Like romosozumab, these are carcinogenic and have a maximum lifetime use of 2 years. The body will begin to break down the bone built by PTH analogs after treatment so use an anti resorptive drug like alendronate for a literal year.

ANTI RESORPTION

Is severely underrated in bone growth as androgens don't preserve bone, they build it. Raloxifene, estrogen, (DHT, is unique in that sense because it has been shown to retain bone mineral density in the absence of both estrogen in testosterone,) and the Bisphosphonate Alendronate. Preventing resorption means more of our androgen GH gains will go towards accruing mass rather than fighting against the breakdown.

ROMOSOZUMAB

Is the most effective bone drug for thickening/widening. It should be used (if at all) after you reach your desired height because its much better at making you wider, not so much taller. PTH analogs are better for making you taller. Carcinogenic, 2 year lifetime use, Yes it is more effective than PTH analogs

TETRANALOGS/MMP INHIBITORS

THREAD. MMP'S break down collagen scaffolding, Inflammation via gear upregulates them. Low dose MMP inhibitors Doxycycline and minocycline prevent this resulting in more bone gains

HOLY GRAIL OGRE GENE DRUGS

remember, These pathways are dictated by genetic expression.

So instead of individually trying to downregulate or upregulate them, why not just alter the gene expression? Obv this is riskiest, epigenetic permanent effects. WE BALL

Vorinostat enjoyers

3 relevant gene drugs available on open market

1. HDAC inhibitor Vorinostat
2. EZH2 inhibitor Tazmetostat
3. DNMT inhibitor azacitidine & oral azacitidine Onureg

Vorinostat
enhances gene transcription. Allows for more genetic expression, indiscriminately. People pair it with androgens to enhance their masculinizing effect. Think of vorinostat as a megaphone. Though because it universally allows for more genetic expression its not just used for androgens. Chronic use is bad for bones, bad for growth, not to mention ur genes being "unlocked" for long period of time thats obviously not good. I would recommend you cycle it but its anti osteogenic effects on bones and such I think is just being drastically outperformed by the amount of gear these people are blasting and thats how they get away with it.

"Though because it universally allows for more genetic expression its not just used for androgens"

Cognitive Improvement by Vorinostat through Modulation of Endoplasmic Reticulum Stress in a Corticosterone-Induced Chronic Stress Model in Mice
Upregulation of HDAC9 in hippocampal neurons mediates depression-like behaviours (eg. Anhedonia) by inhibiting ANXA2 degradation

Vorinostat (SAHA) May Exert Its Antidepressant-Like Effects Through the Modulation of Oxidative Stress Pathways
Vorinostat Corrects Cognitive and Non-Cognitive Symptoms in a Mouse Model of Fragile X Syndrome
The histone deacetylase inhibitor Vorinostat (SAHA ) alleviates depression-like behavior and normalizes epigenetic changes in the hippocampus during ethanol withdrawal
Early-life stress-induced visceral hypersensitivity and anxiety behavior is reversed by histone deacetylase inhibition (Vorinostat).
Suberoylanilide hydroxamic acid attenuates cognitive impairment in offspring caused by maternal surgery during mid-pregnancy
(Vorinostat) SAHA Improves Depressive Symptoms, Cognitive Impairment and Oxidative Stress: Rise of a New Antidepressant Class

TAZMETOSTAT
removes the epigenetic brake on growth genes present during puberty. That re-exposes the programs that let GH and androgens drive growth and masculinization. In adulthood, EZH2 shuts these genes down, the body genetically shifts into maintenance mode instead of growth. So basically, we turn the programs on, blast androgens, BOOM, second puberty. Whereas vstat will exaggerate this growth.

Taz is generally well tolerated, easier to source, and less risky and more specific than vorinostat though they serve two different purposes. There are some drugs that are just better made than others and taz is one of them.

DNMTI azacitidine & oral azacitidine Onureg

stronger more broad version of tazmetosat. Activates PRE PUBERTY growth programs (such as IGF2 natal version of IGF1 which shuts down in puberty forever.) Obviously the ramifications of genetically resensitizing your body to growth on a childhood/fetal level isn't as promising as it is daunting and risky.

Tazmetostat, selective re-activation of pubertal genes >>>> gene signaling for second partial puberty
Onureg, broad and indiscriminate re-activation of core developmental genes

Making vorinostat bioavailable (will need to source raw powder)
Tazmetostat bottles are already formulated, expensive but feasible for the employed.
Onureg oral version of DNTMI azacitidine probably mega expensive IDK. Aza can be pinned subcutaneously, its cheap and easy to source.

SO

If in puberty & want to "ogremaxx" HDACI

Re-run pubertal programs, Taz

Retarded? Azacitidine

GENE PCT. Post cycle to close genes and reduce genetic damage

SAMe
Methyl-B12
Methyl-Folate
Choline
Creatine

These are all supplements.

Thats all for now, good luck.

View attachment 4131629
 

Attachments

  • IMG_6474.jpeg
    IMG_6474.jpeg
    32.3 KB · Views: 0
  • +1
Reactions: gigacumster3000
Theoretical effects of re activating natal IGF-2 via azacitidine

GH converts to IGF1 which is primary pathway for pubertal/adult growth in human body

2-3x stronger than GH for craniofacial bone remodeling
2x stronger than GH for periosteal bone thickening
negligible for muscle hypertrophy
IGF2 REGULATES facial bone structure development in children. GH does not.

This could theoretically "re-roll" musculature and skeletal structure physique through re structuring the makeup from a top down perspective. The genetic pathway. Because IGF2 regulates growth in such a significant manner, it can SHIFT skeletal and muscular proportions. obv we are blasting androgens it will bias them towards masculine proportioning.

The most obvious should be facial remodeling.
Cope
 
When did u start? Also how much does it cost
Little over a month ago

Steady progress, wider bidelt, hairline regrew, lashes longer, frame filling out.

constantly reconfiguring stack as I learn more
 
IndiaMART mental masturbation

a bunch of experimental huh?
 
anyway i copypasted your entire post onto gpt5 and this was the conversation:





Big picture
  • Longitudinal growth = growth-plate biology (chondrocytes) under GH/IGF-1 + sex steroids + local regulators (WNT/β-catenin, FGFs, TGF-β). Estrogen via ERα is the key fuse for epiphyseal closure in both sexes; blocking it can delay fusion but risks bone/ metabolic harm and isn’t a magic “height unlock.” E-APEM+1
Where it’s accurate (directionally)
  • Estrogen drives plate closure. True mechanistically; clinical attempts to delay closure (e.g., AIs in select boys) show modest gains with careful monitoring—nowhere near the claims implied. E-APEM+2PMC+2
  • FGFR3 over-activity restricts growth (achondroplasia). Targeting that pathway can help growth in specific genetic conditions—but not by pan-FGFR cancer drugs. (See “What’s off.”) U.S. Food and Drug Administration
What’s off / risky
  • “GH/IGF-1 is the most important.” It’s crucial but not singular; excess GH/IGF-1 can actually advance growth-plate senescence/ossification timing. (Clinical and basic literature support estrogen-mediated senescence + complex local cues, not a single throttle.) E-APEM
  • Romosozumab: not carcinogenic “2-year max” for that reason. It’s a sclerostin inhibitor for osteoporosis with a cardiovascular risk warning, primarily increases bone mass/width, not height; no height indication. NCBI+2MDEdge+2
  • Teriparatide/abaloparatide: intermittent PTH analogs that raise bone formation; used for osteoporosis, not height. The historical osteosarcoma rat signal led to limits; FDA later removed the boxed warning for teriparatide (still generally limited to ~2 years of lifetime use in guidance). Abaloparatide labeling/guidelines still recommend a 2-year lifetime cap. UHC Provider+3FDA Access Data+3FDA Access Data+3
  • FGFR “infigratinib to kickstart growth.” Infigratinib is an oncology pan-FGFR inhibitor with notable ocular and metabolic toxicities; not an endorsed strategy for height. The pediatric growth advance in achondroplasia is from vosoritide (CNP analogue to boost NPR2/cGMP)different pathway, not FGFR inhibition. investors.biomarin.com+5PMC+5ScienceDirect+5
  • KY19382 / “height pills.” KY19382 is an experimental WNT/β-catenin activator studied mainly for hair/skin; no human evidence for height or safe skeletal longitudinal use. Systemic WNT activation carries tumor/ectopic bone risks. PMC+1
  • “DHT uniquely preserves BMD without estrogen.” Evidence doesn’t support using non-aromatizable androgens to maintain adolescent bone health; estrogen signaling is central for peak bone mass and plate fusion physiology. Over-suppression of E2 harms bone. E-APEM
  • “AI + supraphysiologic GH/androgens → supraphysiologic height 13–24.” Human data don’t support that claim. Trials of AIs in teen boys show small gains with monitoring; stacking GH + high-dose androgens while suppressing E2 is not an evidence-based or safe “height protocol.” PMC+1
  • Epigenetic drugs (vorinostat, tazmetostat, azacitidine) for ‘second puberty’. These are potent anticancer agents (HDAC, EZH2, DNMT inhibitors) with systemic risks; claims about controlled “growth program re-activation” outside cancer care are speculative and hazardous. (No clinical evidence for safe height/dimorphism use.)
  • MMP inhibition (doxy/mino) to boost bone. Tetracyclines can inhibit MMPs, but chronic antibiotic use for “bone gains” is not standard care and brings microbiome and resistance risks.
What the evidence actually supports for height (medical context only)
  • Treat the diagnosis: GH for GH deficiency/SGA non-catch-up; vosoritide for achondroplasia (and investigational expansion in certain gene-defined short stature); selected use of AIs or GnRHa in narrow scenarios under pediatric endocrine care. U.S. Food and Drug Administration+2investors.biomarin.com+2
  • Protect bone while growing: adequate calcium/vitamin D, nutrition, sleep, mechanical loading; avoid chronic low E2 states. (When potent anabolics/antiresorptives are used for osteoporosis, they’re sequenced and monitored—not aimed at height.) E-APEM
Bottom line
  • Parts of that post mix real pathway names with oncology drugs and research molecules in ways that are not supported for height and carry serious risk. The pieces that are clinically validated (GH for specific diagnoses; vosoritide for achondroplasia; cautious AI use in select boys) show modest, diagnosis-dependent effects—not the “ogre” outcomes implied. If you want, I can map a clean, evidence-based pathway chart (what up- or down-regulates plates, where the approved meds sit, and what’s speculative) and keep it tight.

You said:​

think theoretically, use your expertise and think about possibility and theory. b

ChatGPT said:​

Got it. Here’s the clean, theoretical map—no protocols, just “what would need to be true” for longitudinal growth to move, and where the real bottlenecks live.

Core first-principles​

Long bone lengthening hinges on three levers inside the growth plate:
  1. Pool size of resting/proliferative chondrocytes
  2. Tempo of hypertrophy → calcification → vascular invasion
  3. Senescence/closure programs (intrinsic clock + estrogen/ERα trigger)
Push (1) up, modulate (2), delay (3) = more length. Push too hard on (2) or (3) the wrong way = faster closure or fragile bone.

Theoretical “knobs” (systems → local)​

  1. Estrogen gating (ERα)
    • Theory: tissue-selective dialing at the plate (local SERM/SERD bias) to blunt fusion signaling without tanking systemic E2 needed for bone quality, brain, libido, etc.
    • Hard part: spatial selectivity—systemic suppression predictably harms bone.
  2. GH/IGF-1 amplitude & pulsatility
    • Theory: keep IGF-1 in an optimal window that sustains proliferation without accelerating hypertrophic zone expansion/senescence. Pulses > constant bath.
    • Failure mode: chronically high IGF-1 speeds the growth clock, not just length.
  3. CNP/NPR2 (cGMP) axis vs FGFR3
    • Theory: bias toward CNP/NPR2 signaling to counter FGFR3 brake (the body’s height “governor”).
    • Cleaner than pan-FGFR blockade: enhance downstream NPR2 activity (positive allosteric modulators) or local CNP analog delivery to plates.
    • Constraint: delivery and dosing kinetics at the physis.
  4. Ihh–PTHrP feedback loop
    • Theory: gently extending PTHrP tone prolongs the proliferative zone.
    • Risk: overdoing it stalls maturation; underdoing it changes nothing.
  5. WNT/β-catenin timing
    • Theory: brief, spatially confined nudges might enhance matrix and osteoblast support around the plate, but systemic activation risks ectopic bone/tumors and may bias width (periosteal activity) more than length.
    • If used at all (in animals), it would need micro-dosed, local, and transient.
  6. TGF-β / BMP balance
    • Theory: reduce fibrosis/inflammation around the physis (TGF-β overdrive stiffens ECM and can choke remodeling) while preserving TGF-β’s role in orderly cartilage matrix.
    • Translation challenge: “anti-fibrotic” ≠ “pro-length”—too much suppression destabilizes repair.
  7. Senescence pathways (p16/p21, mTOR, SASP)
    • Theory: slow the accrual of senescent chondro-progenitors (mild mTOR modulation; anti-SASP strategies) so the stem-like pool lasts longer.
    • Risks: systemic longevity levers can impair anabolism or growth when mistimed.
  8. Angio-timing (VEGF)
    • Theory: slightly delaying vascular invasion into hypertrophic cartilage could add cell cycles before ossification.
    • Big risk: delay vascularity too much → weak, undermineralized cartilage.
  9. ECM remodeling (MMP/TIMP, cross-linking)
    • Theory: keep MMP activity in a physiologic window to allow replacement with net gain; blunt chronic inflammatory surge that over-degrades scaffolds.
    • Over-suppression of MMPs = poor remodeling and brittleness.
  10. Mechanobiology
  • Theory: controlled, intermittent loading patterns (Hueter–Volkmann principles) bias local growth rates; asymmetry can be corrected or worsened depending on vectors.
  • Hard part: dosing forces precisely at physes without injury.
  1. Chronobiology
  • Theory: align anabolic signals with natural GH pulses (sleep-anchored), not constant exposure; circadian misalignment shortens the useful window.

“What would need to be true” scenarios (thought experiments)​

  • Length-first, width-later sequencing
    • Phase A (open plates): preserve proliferative pool (CNP/NPR2 bias, gentle IGF-1 zone), avoid deep E2 suppression, curb inflammation/fibrosis near plates.
    • Phase B (after closure/near-closure): enhance mass/width and microarchitecture (periosteal—e.g., sclerostin blockade concepts) to harden the scaffold.
    • Rationale: different levers move length vs robustness.
  • Local-first pharmacology
    • Hypothesis: micro-reservoirs or hydrogels delivering plate-targeted cues (CNP analog, PTHrP-mimetic, anti-SASP) outperform any systemic agent on risk/benefit, because off-target bone and tumor risk scale with exposure.
  • Senescence-aware IGF strategy
    • Hypothesis: moderate IGF-1 with high pulsatility + senescence-brake support (anti-SASP, redox control) maintains proliferation longer than high IGF-1 that burns the clock fast.

What’s fundamentally hard​

  • Spatial selectivity: Systemic switches (WNT, TGF-β, epigenetic drugs) act everywhere; plates are tiny targets immersed in whole-body risk.
  • The developmental clock: Epigenetic maturation, not just hormones, pushes plates toward closure. Rewinding that clock broadly risks dysplasia or neoplasia.
  • Trade-offs: Every “more growth” lever has a paired failure mode (fragility, asymmetric growth, fibrosis, tumorigenesis, vascular issues, neuropsych side-effects).

Experiments that would actually answer this (preclinical)​

  • Human growth-plate organoids + microfluidics to titrate IGF-1/CNP/ERα inputs while reading single-cell states (proliferation vs hypertrophy vs senescence).
  • In vivo local-delivery trials (large animals): biodegradable depots at physes with trackable reporters for WNT/cGMP activity; measure true length change, not just BMD.
  • Biomechanics rigs to “dose” compressive/tensile cycles and map mechano-transduction to Ihh–PTHrP and NPR2 signaling.
  • Longitudinal multi-omics of plate stem-like cells to identify reversible vs irreversible checkpoints (which epigenetic marks are cause, not consequence).

Practical guardrails (even in theory)​

  • Don’t tank estrogen systemically if you care about bone quality and brain.
  • Avoid chronic, flat, supraphysiologic IGF-1 exposure; favor pulse logic.
  • Prefer local, time-boxed modulation over systemic, chronic switches.
  • Separate length goals (during the true window) from strength/width goals (periosteal, lifelong).
If you want, I can turn this into a one-page “pathway → lever → expected effect → main failure mode” table you can glance at before you read any forum takes.

You said:​

i was talking about all thr drugs/inhibitors and etc mentioned

ChatGPT said:​

Got it—here’s a tight, theory-first pass on every drug/class you listed: what switch it flips, how that could touch longitudinal growth, and the biggest failure modes. Not advice; many are oncology/controlled meds with serious risks.

GH/IGF-1 axis​

Recombinant hGH (somatropin)
  • Switch: ↑ GH → ↑ hepatic/local IGF-1 → chondrocyte proliferation.
  • Theoretical upside: more cell cycles → ↑ height velocity if plates open.
  • Failure modes: chronically high IGF-1 can accelerate hypertrophy/senescence → earlier “clock burn”; edema, insulin resistance, acromegaloid soft-tissue changes.

Estrogen axis (the fuse for fusion)​

Letrozole (AI)
  • Switch: ↓ aromatization → ↓ E2.
  • Theoretical upside: delay ERα-mediated fusion.
  • Failure modes: harms bone quality, lipids, mood/brain; unpredictable plate biology if E2 is too low.
Raloxifene (SERM)
  • Switch: tissue-selective ER modulation.
  • Theoretical upside: preserve bone anti-resorption and CNS benefits while sparing plate-closure signaling.
  • Failure modes: not validated for height; thrombotic risk; plate ER context may not be truly “spared.”

WNT/β-catenin axis​

Romosozumab (sclerostin mAb)
  • Switch: disinhibits WNT in bone → strong osteo-anabolism (periosteal/width).
  • Theoretical upside: thickens cortices/width, not length.
  • Failure modes: CV risk signal; no growth-plate indication; systemic WNT push ≠ taller.
KY19382 (experimental WNT activator)
  • Switch: boosts β-catenin signaling (shown mainly in skin/hair preclinical).
  • Theoretical upside: speculative scaffold support.
  • Failure modes: tumor/ectopic bone risk with systemic WNT; zero human height data.

FGFR3 brake​

Infigratinib (pan-FGFR TKI; oncology)
  • Switch: inhibits FGFRs (incl. FGFR3).
  • Theoretical upside: releases “height governor” locally.
  • Failure modes: off-target toxicities (ocular, phosphate handling, mucosa); non-selective; not a viable height strategy. (In achondroplasia, the validated counter-pathway is CNP/NPR2, not systemic FGFR blockade.)

TGF-β / anti-fibrotic tone​

Pirfenidone; Losartan
  • Switch: dampen pro-fibrotic TGF-β signaling (pirfenidone directly; ARB indirectly).
  • Theoretical upside: less periphyseal fibrosis/inflammation → cleaner remodeling milieu.
  • Failure modes: “anti-fibrotic” ≠ “pro-length”; over-dampening impairs orderly matrix turnover; pirfenidone GI/hepatic issues.

Androgens (dimorphism + bone anabolism; E2 still rules fusion)​

Testosterone enanthate
  • Switch: androgen receptor agonism; aromatizes to E2; some 5α→DHT.
  • Theoretical upside: ↑ height velocity (via AR + GH synergy) while plates open; ↑ BMD.
  • Failure modes: pushes pubertal clock; E2 from T can hasten fusion; cardiometabolic, psychiatric, fertility suppression without gonadotropin support.
Trenbolone enanthate (non-aromatizing)
  • Switch: potent AR agonist; no E2.
  • Theoretical upside: preserves AR anabolism without added E2 load.
  • Failure modes: notorious neuro/renal/night-sweats/prolactin issues; zero rationale for height; E2 deficiency harms bone/brain.
DHT “support” idea
  • Switch: strong AR, non-aromatizing.
  • Theoretical upside: density/strength claims get floated.
  • Failure modes: cannot substitute for E2 in adolescent bone biology; hair/skin/HDL hit.

Bone anabolics (PTH analogs)​

Teriparatide; Abaloparatide
  • Switch: intermittent PTH1R activation → net bone formation (remodeling-led).
  • Theoretical upside: improves microarchitecture; speculative support around plates.
  • Failure modes: not for height; hypercalcemia, dizziness; lifetime exposure limits; gains regress without anti-resorptive consolidation.

Anti-resorptives​

Alendronate (bisphosphonate)
  • Switch: inhibits osteoclasts → ↓ resorption.
  • Theoretical upside: “locks in” mass built elsewhere.
  • Failure modes: can oversuppress remodeling → brittle bone, atypical femur risk long-term; no effect on plate lengthening.

MMP modulation​

Doxycycline/Minocycline (low-dose MMP inhibition)
  • Switch: ↓ MMP-driven collagen degradation.
  • Theoretical upside: steadier ECM scaffold during anabolism.
  • Failure modes: oversuppression impairs healthy remodeling; microbiome/resistance; no height data.

Epigenetic “gene drugs”​

Vorinostat (HDACi)
  • Switch: broad ↑ transcriptional accessibility.
  • Theoretical upside: amplifies growth/dimorphism programs if present.
  • Failure modes: indiscriminate; anti-osteogenic signals possible; cytopenias, GI, fatigue; no controlled “second-puberty” use.
Tazmetostat (EZH2 inhibitor)
  • Switch: removes PRC2 repression (re-opens some growth programs).
  • Theoretical upside: conceptually “puberty program re-exposure.”
  • Failure modes: oncologic med; secondary malignancy risk; systemic derepression is not plate-targeted.
Azacitidine / Onureg (DNMT inhibitors)
  • Switch: DNA hypomethylation → very broad gene reactivation.
  • Theoretical upside: fetal/early growth program re-awakening (IGF2, etc.) in theory.
  • Failure modes: high-toxicity chemo; marrow suppression, infections; extreme dysmorph/tumor risk conceptually; no place in height.

Hair/skin & ancillary​

GHK-Cu
  • Switch: wound-healing/ECM signaling peptide.
  • Theoretical upside: local skin/ECM quality; no plate effect.
  • Failure modes: cosmetic gains only; no height role.
Finasteride/Dutasteride; RU58841
  • Switch: 5-ARI systemic (fin/dut); topical AR antagonist (RU; research chem).
  • Theoretical upside: mitigate DHT hair/skin effects during androgen use.
  • Failure modes: sexual/psych sides (5-ARIs); RU systemic absorption unknown.
AIs (class, again)
  • See above—blunt E2, risk bone/CNS; theoretical delay of fusion at real costs.
ARBs (Losartan/Telmisartan)
  • Switch: BP control; some PPAR-γ/anti-fibrotic (telmisartan).
  • Theoretical upside: safer hemodynamics on androgens; minor ECM tone effects.
  • Failure modes: hypotension, renal K+ issues.

Gonadotropins​

hCG / hMG
  • Switch: mimic LH (±FSH with hMG) → support testicular steroidogenesis/spermatogenesis.
  • Theoretical upside: preserve fertility axis during exogenous androgens.
  • Failure modes: E2 rises via intratesticular aromatase; gynecomastia risk; not a height lever.

“Gene PCT” supplements (SAMe, methyl-B12, methyl-folate, choline, creatine)​

  • Switch: methyl-donor pool, one-carbon metabolism, ATP buffering.
  • Theoretical upside: general metabolic support; no meaningful “close the genes” effect at the growth-plate level.
  • Failure modes: minimal if dosed sanely; don’t expect epigenetic reversals.

Net theoretical takeaways​

  • Length is a chondrocyte-cycle problem (IGF-1/Ihh–PTHrP/CNP vs ERα clock). Most agents above are bone mass/width levers or systemic sledgehammers.
  • The only pathway with clean, plate-centric pro-length logic in humans so far is CNP/NPR2 biasing vs FGFR3, and even that’s diagnosis-bound.
  • Systemic WNT, epigenetic drugs, pan-FGFR TKIs, non-aromatizing AAS: big, non-selective risks with no human height evidence.
  • AI-heavy strategies trade a possible delay in fusion for bone/CNS harm and still don’t guarantee added length.
If you want, I’ll condense this into a one-page matrix (Drug/Class → Primary switch → Plausible effect on length/width → Key failure mode → Evidence level) so you can scan it at a glance.
 
KY19382 0.25 mg/day? I thought it was 0.1 mg/kg/day

Thread 'KY19382, THE ULTIMATE HEIGHTMAX DRUG' https://looksmax.org/threads/ky19382-the-ultimate-heightmax-drug.1100197/
heres a chatgpt fact check

Got it—here’s a tight fact-check on the KY19382 claims.


KY19382 & pathway basics​


  • What it is (supported): A research small molecule that activates Wnt/β-catenin by dual actions: disrupting CXXC5–Dishevelled interaction and inhibiting GSK-3β, thereby stabilizing β-catenin. Most data are preclinical (cells, mice), with strongest results in hair regrowth and wound models. (PMC)
  • CXXC5 role (supported): CXXC5 (IDAX) is a negative regulator of Wnt/β-catenin; blocking CXXC5–DVL can activate Wnt signaling. (PMC)
  • GSK-3β → β-catenin destruction (textbook): In the destruction complex, GSK-3β phosphorylation targets β-catenin for degradation; inhibiting GSK-3β stabilizes β-catenin. (PMC)

Growth plate / chondrocyte claims​


  • “β-catenin activation enhances proliferation and delays maturation”Oversimplified / context-dependent. Canonical Wnt/β-catenin is required for growth-plate organization and can promote proliferation, but many studies show it drives hypertrophy/maturation rather than delaying it; effects vary by dose, zone, and developmental stage. (PMC)
  • “KY19382 delays chondrocyte maturation/ossification and completely stops closureUnsupported. A mouse study targeting CXXC5 suggests delayed growth-plate senescence and increased growth-plate height with KY19382, but no evidence of complete closure arrest, and no human data. (ResearchGate)
  • “Extends the active period of growth plates”Preclinical-only. The concept (delay senescence) is shown in mice; translation to humans is unknown. (Life Science Alliance)
  • “Modulates FGFR activity / mirrors FGFR3 inhibitors”Not supported. KY19382’s described mechanism is CXXC5–DVL & GSK-3β, not FGFR modulation. Equating it with FGFR3 inhibitors is incorrect. (MedChem Express)

Other claimed effects​


  • “Supports bone formation and repair”Speculative. Wnt/β-catenin activation can aid osteogenesis in general, and CXXC5 inhibition promotes osteoblast differentiation in models, but KY19382 has no clinical evidence for bone repair. (PMC)
  • “Promotes chondrocyte proliferation”Plausible preclinically via Wnt activation; again, no human proof. (ScienceDirect)
  • “Helps hair growth”Supported (preclinical). Multiple mouse/skin models show hair regrowth & neogenesis with KY19382 via Wnt/β-catenin activation. (PMC)
  • “Preserves height throughout the day via cartilage production”False. Daily height loss is mainly from intervertebral disc fluid shifts, not acute growth-plate cartilage output; no evidence KY19382 changes diurnal stature. (actaorthop.org)
  • “Younger skin”Speculative. Wnt signaling influences skin biology, but no clinical data show KY19382 rejuvenates skin. (Hair/wound studies ≠ anti-aging skin trial.) (Europe PMC)

Safety & reality check​


  • Clinical status: KY19382 is a research reagent, not an approved drug. No human dosing, safety, or efficacy trials published.
  • On-target risk: Systemic Wnt/β-catenin activation has oncogenic potential; any systemic use would demand rigorous safety evaluation. (Oncotarget)

Verdict (one-liners)​


  • Chondrocyte/growth-plate primer: basically right. (jocmr.org)
  • KY19382 mechanism (CXXC5/DVL + GSK-3β → Wnt↑): true (preclinical). (PMC)
  • “Delays maturation / stops closure”: delay (mouse) plausible; ‘stops closure’ = unsupported. (ResearchGate)
  • “FGFR modulation / FGFR3 inhibitor-like”: unsupported/incorrect. (MedChem Express)
  • Hair growth: supported (animal/skin models). (PMC)
  • Preserve daytime height / youthful skin: no evidence. (actaorthop.org)
 
anyway i copypasted your entire post onto gpt5 and this was the conversation:





Big picture
  • Longitudinal growth = growth-plate biology (chondrocytes) under GH/IGF-1 + sex steroids + local regulators (WNT/β-catenin, FGFs, TGF-β). Estrogen via ERα is the key fuse for epiphyseal closure in both sexes; blocking it can delay fusion but risks bone/ metabolic harm and isn’t a magic “height unlock.” E-APEM+1
Where it’s accurate (directionally)
  • Estrogen drives plate closure. True mechanistically; clinical attempts to delay closure (e.g., AIs in select boys) show modest gains with careful monitoring—nowhere near the claims implied. E-APEM+2PMC+2
  • FGFR3 over-activity restricts growth (achondroplasia). Targeting that pathway can help growth in specific genetic conditions—but not by pan-FGFR cancer drugs. (See “What’s off.”) U.S. Food and Drug Administration
What’s off / risky
  • “GH/IGF-1 is the most important.” It’s crucial but not singular; excess GH/IGF-1 can actually advance growth-plate senescence/ossification timing. (Clinical and basic literature support estrogen-mediated senescence + complex local cues, not a single throttle.) E-APEM
  • Romosozumab: not carcinogenic “2-year max” for that reason. It’s a sclerostin inhibitor for osteoporosis with a cardiovascular risk warning, primarily increases bone mass/width, not height; no height indication. NCBI+2MDEdge+2
  • Teriparatide/abaloparatide: intermittent PTH analogs that raise bone formation; used for osteoporosis, not height. The historical osteosarcoma rat signal led to limits; FDA later removed the boxed warning for teriparatide (still generally limited to ~2 years of lifetime use in guidance). Abaloparatide labeling/guidelines still recommend a 2-year lifetime cap. UHC Provider+3FDA Access Data+3FDA Access Data+3
  • FGFR “infigratinib to kickstart growth.” Infigratinib is an oncology pan-FGFR inhibitor with notable ocular and metabolic toxicities; not an endorsed strategy for height. The pediatric growth advance in achondroplasia is from vosoritide (CNP analogue to boost NPR2/cGMP)different pathway, not FGFR inhibition. investors.biomarin.com+5PMC+5ScienceDirect+5
  • KY19382 / “height pills.” KY19382 is an experimental WNT/β-catenin activator studied mainly for hair/skin; no human evidence for height or safe skeletal longitudinal use. Systemic WNT activation carries tumor/ectopic bone risks. PMC+1
  • “DHT uniquely preserves BMD without estrogen.” Evidence doesn’t support using non-aromatizable androgens to maintain adolescent bone health; estrogen signaling is central for peak bone mass and plate fusion physiology. Over-suppression of E2 harms bone. E-APEM
  • “AI + supraphysiologic GH/androgens → supraphysiologic height 13–24.” Human data don’t support that claim. Trials of AIs in teen boys show small gains with monitoring; stacking GH + high-dose androgens while suppressing E2 is not an evidence-based or safe “height protocol.” PMC+1
  • Epigenetic drugs (vorinostat, tazmetostat, azacitidine) for ‘second puberty’. These are potent anticancer agents (HDAC, EZH2, DNMT inhibitors) with systemic risks; claims about controlled “growth program re-activation” outside cancer care are speculative and hazardous. (No clinical evidence for safe height/dimorphism use.)
  • MMP inhibition (doxy/mino) to boost bone. Tetracyclines can inhibit MMPs, but chronic antibiotic use for “bone gains” is not standard care and brings microbiome and resistance risks.
What the evidence actually supports for height (medical context only)
  • Treat the diagnosis: GH for GH deficiency/SGA non-catch-up; vosoritide for achondroplasia (and investigational expansion in certain gene-defined short stature); selected use of AIs or GnRHa in narrow scenarios under pediatric endocrine care. U.S. Food and Drug Administration+2investors.biomarin.com+2
  • Protect bone while growing: adequate calcium/vitamin D, nutrition, sleep, mechanical loading; avoid chronic low E2 states. (When potent anabolics/antiresorptives are used for osteoporosis, they’re sequenced and monitored—not aimed at height.) E-APEM
Bottom line
  • Parts of that post mix real pathway names with oncology drugs and research molecules in ways that are not supported for height and carry serious risk. The pieces that are clinically validated (GH for specific diagnoses; vosoritide for achondroplasia; cautious AI use in select boys) show modest, diagnosis-dependent effects—not the “ogre” outcomes implied. If you want, I can map a clean, evidence-based pathway chart (what up- or down-regulates plates, where the approved meds sit, and what’s speculative) and keep it tight.

You said:​

think theoretically, use your expertise and think about possibility and theory. b

ChatGPT said:​

Got it. Here’s the clean, theoretical map—no protocols, just “what would need to be true” for longitudinal growth to move, and where the real bottlenecks live.

Core first-principles​

Long bone lengthening hinges on three levers inside the growth plate:
  1. Pool size of resting/proliferative chondrocytes
  2. Tempo of hypertrophy → calcification → vascular invasion
  3. Senescence/closure programs (intrinsic clock + estrogen/ERα trigger)
Push (1) up, modulate (2), delay (3) = more length. Push too hard on (2) or (3) the wrong way = faster closure or fragile bone.

Theoretical “knobs” (systems → local)​

  1. Estrogen gating (ERα)
    • Theory: tissue-selective dialing at the plate (local SERM/SERD bias) to blunt fusion signaling without tanking systemic E2 needed for bone quality, brain, libido, etc.
    • Hard part: spatial selectivity—systemic suppression predictably harms bone.
  2. GH/IGF-1 amplitude & pulsatility
    • Theory: keep IGF-1 in an optimal window that sustains proliferation without accelerating hypertrophic zone expansion/senescence. Pulses > constant bath.
    • Failure mode: chronically high IGF-1 speeds the growth clock, not just length.
  3. CNP/NPR2 (cGMP) axis vs FGFR3
    • Theory: bias toward CNP/NPR2 signaling to counter FGFR3 brake (the body’s height “governor”).
    • Cleaner than pan-FGFR blockade: enhance downstream NPR2 activity (positive allosteric modulators) or local CNP analog delivery to plates.
    • Constraint: delivery and dosing kinetics at the physis.
  4. Ihh–PTHrP feedback loop
    • Theory: gently extending PTHrP tone prolongs the proliferative zone.
    • Risk: overdoing it stalls maturation; underdoing it changes nothing.
  5. WNT/β-catenin timing
    • Theory: brief, spatially confined nudges might enhance matrix and osteoblast support around the plate, but systemic activation risks ectopic bone/tumors and may bias width (periosteal activity) more than length.
    • If used at all (in animals), it would need micro-dosed, local, and transient.
  6. TGF-β / BMP balance
    • Theory: reduce fibrosis/inflammation around the physis (TGF-β overdrive stiffens ECM and can choke remodeling) while preserving TGF-β’s role in orderly cartilage matrix.
    • Translation challenge: “anti-fibrotic” ≠ “pro-length”—too much suppression destabilizes repair.
  7. Senescence pathways (p16/p21, mTOR, SASP)
    • Theory: slow the accrual of senescent chondro-progenitors (mild mTOR modulation; anti-SASP strategies) so the stem-like pool lasts longer.
    • Risks: systemic longevity levers can impair anabolism or growth when mistimed.
  8. Angio-timing (VEGF)
    • Theory: slightly delaying vascular invasion into hypertrophic cartilage could add cell cycles before ossification.
    • Big risk: delay vascularity too much → weak, undermineralized cartilage.
  9. ECM remodeling (MMP/TIMP, cross-linking)
    • Theory: keep MMP activity in a physiologic window to allow replacement with net gain; blunt chronic inflammatory surge that over-degrades scaffolds.
    • Over-suppression of MMPs = poor remodeling and brittleness.
  10. Mechanobiology
  • Theory: controlled, intermittent loading patterns (Hueter–Volkmann principles) bias local growth rates; asymmetry can be corrected or worsened depending on vectors.
  • Hard part: dosing forces precisely at physes without injury.
  1. Chronobiology
  • Theory: align anabolic signals with natural GH pulses (sleep-anchored), not constant exposure; circadian misalignment shortens the useful window.

“What would need to be true” scenarios (thought experiments)​

  • Length-first, width-later sequencing
    • Phase A (open plates): preserve proliferative pool (CNP/NPR2 bias, gentle IGF-1 zone), avoid deep E2 suppression, curb inflammation/fibrosis near plates.
    • Phase B (after closure/near-closure): enhance mass/width and microarchitecture (periosteal—e.g., sclerostin blockade concepts) to harden the scaffold.
    • Rationale: different levers move length vs robustness.
  • Local-first pharmacology
    • Hypothesis: micro-reservoirs or hydrogels delivering plate-targeted cues (CNP analog, PTHrP-mimetic, anti-SASP) outperform any systemic agent on risk/benefit, because off-target bone and tumor risk scale with exposure.
  • Senescence-aware IGF strategy
    • Hypothesis: moderate IGF-1 with high pulsatility + senescence-brake support (anti-SASP, redox control) maintains proliferation longer than high IGF-1 that burns the clock fast.

What’s fundamentally hard​

  • Spatial selectivity: Systemic switches (WNT, TGF-β, epigenetic drugs) act everywhere; plates are tiny targets immersed in whole-body risk.
  • The developmental clock: Epigenetic maturation, not just hormones, pushes plates toward closure. Rewinding that clock broadly risks dysplasia or neoplasia.
  • Trade-offs: Every “more growth” lever has a paired failure mode (fragility, asymmetric growth, fibrosis, tumorigenesis, vascular issues, neuropsych side-effects).

Experiments that would actually answer this (preclinical)​

  • Human growth-plate organoids + microfluidics to titrate IGF-1/CNP/ERα inputs while reading single-cell states (proliferation vs hypertrophy vs senescence).
  • In vivo local-delivery trials (large animals): biodegradable depots at physes with trackable reporters for WNT/cGMP activity; measure true length change, not just BMD.
  • Biomechanics rigs to “dose” compressive/tensile cycles and map mechano-transduction to Ihh–PTHrP and NPR2 signaling.
  • Longitudinal multi-omics of plate stem-like cells to identify reversible vs irreversible checkpoints (which epigenetic marks are cause, not consequence).

Practical guardrails (even in theory)​

  • Don’t tank estrogen systemically if you care about bone quality and brain.
  • Avoid chronic, flat, supraphysiologic IGF-1 exposure; favor pulse logic.
  • Prefer local, time-boxed modulation over systemic, chronic switches.
  • Separate length goals (during the true window) from strength/width goals (periosteal, lifelong).
If you want, I can turn this into a one-page “pathway → lever → expected effect → main failure mode” table you can glance at before you read any forum takes.

You said:​

i was talking about all thr drugs/inhibitors and etc mentioned

ChatGPT said:​

Got it—here’s a tight, theory-first pass on every drug/class you listed: what switch it flips, how that could touch longitudinal growth, and the biggest failure modes. Not advice; many are oncology/controlled meds with serious risks.

GH/IGF-1 axis​

Recombinant hGH (somatropin)
  • Switch: ↑ GH → ↑ hepatic/local IGF-1 → chondrocyte proliferation.
  • Theoretical upside: more cell cycles → ↑ height velocity if plates open.
  • Failure modes: chronically high IGF-1 can accelerate hypertrophy/senescence → earlier “clock burn”; edema, insulin resistance, acromegaloid soft-tissue changes.

Estrogen axis (the fuse for fusion)​

Letrozole (AI)
  • Switch: ↓ aromatization → ↓ E2.
  • Theoretical upside: delay ERα-mediated fusion.
  • Failure modes: harms bone quality, lipids, mood/brain; unpredictable plate biology if E2 is too low.
Raloxifene (SERM)
  • Switch: tissue-selective ER modulation.
  • Theoretical upside: preserve bone anti-resorption and CNS benefits while sparing plate-closure signaling.
  • Failure modes: not validated for height; thrombotic risk; plate ER context may not be truly “spared.”

WNT/β-catenin axis​

Romosozumab (sclerostin mAb)
  • Switch: disinhibits WNT in bone → strong osteo-anabolism (periosteal/width).
  • Theoretical upside: thickens cortices/width, not length.
  • Failure modes: CV risk signal; no growth-plate indication; systemic WNT push ≠ taller.
KY19382 (experimental WNT activator)
  • Switch: boosts β-catenin signaling (shown mainly in skin/hair preclinical).
  • Theoretical upside: speculative scaffold support.
  • Failure modes: tumor/ectopic bone risk with systemic WNT; zero human height data.

FGFR3 brake​

Infigratinib (pan-FGFR TKI; oncology)
  • Switch: inhibits FGFRs (incl. FGFR3).
  • Theoretical upside: releases “height governor” locally.
  • Failure modes: off-target toxicities (ocular, phosphate handling, mucosa); non-selective; not a viable height strategy. (In achondroplasia, the validated counter-pathway is CNP/NPR2, not systemic FGFR blockade.)

TGF-β / anti-fibrotic tone​

Pirfenidone; Losartan
  • Switch: dampen pro-fibrotic TGF-β signaling (pirfenidone directly; ARB indirectly).
  • Theoretical upside: less periphyseal fibrosis/inflammation → cleaner remodeling milieu.
  • Failure modes: “anti-fibrotic” ≠ “pro-length”; over-dampening impairs orderly matrix turnover; pirfenidone GI/hepatic issues.

Androgens (dimorphism + bone anabolism; E2 still rules fusion)​

Testosterone enanthate
  • Switch: androgen receptor agonism; aromatizes to E2; some 5α→DHT.
  • Theoretical upside: ↑ height velocity (via AR + GH synergy) while plates open; ↑ BMD.
  • Failure modes: pushes pubertal clock; E2 from T can hasten fusion; cardiometabolic, psychiatric, fertility suppression without gonadotropin support.
Trenbolone enanthate (non-aromatizing)
  • Switch: potent AR agonist; no E2.
  • Theoretical upside: preserves AR anabolism without added E2 load.
  • Failure modes: notorious neuro/renal/night-sweats/prolactin issues; zero rationale for height; E2 deficiency harms bone/brain.
DHT “support” idea
  • Switch: strong AR, non-aromatizing.
  • Theoretical upside: density/strength claims get floated.
  • Failure modes: cannot substitute for E2 in adolescent bone biology; hair/skin/HDL hit.

Bone anabolics (PTH analogs)​

Teriparatide; Abaloparatide
  • Switch: intermittent PTH1R activation → net bone formation (remodeling-led).
  • Theoretical upside: improves microarchitecture; speculative support around plates.
  • Failure modes: not for height; hypercalcemia, dizziness; lifetime exposure limits; gains regress without anti-resorptive consolidation.

Anti-resorptives​

Alendronate (bisphosphonate)
  • Switch: inhibits osteoclasts → ↓ resorption.
  • Theoretical upside: “locks in” mass built elsewhere.
  • Failure modes: can oversuppress remodeling → brittle bone, atypical femur risk long-term; no effect on plate lengthening.

MMP modulation​

Doxycycline/Minocycline (low-dose MMP inhibition)
  • Switch: ↓ MMP-driven collagen degradation.
  • Theoretical upside: steadier ECM scaffold during anabolism.
  • Failure modes: oversuppression impairs healthy remodeling; microbiome/resistance; no height data.

Epigenetic “gene drugs”​

Vorinostat (HDACi)
  • Switch: broad ↑ transcriptional accessibility.
  • Theoretical upside: amplifies growth/dimorphism programs if present.
  • Failure modes: indiscriminate; anti-osteogenic signals possible; cytopenias, GI, fatigue; no controlled “second-puberty” use.
Tazmetostat (EZH2 inhibitor)
  • Switch: removes PRC2 repression (re-opens some growth programs).
  • Theoretical upside: conceptually “puberty program re-exposure.”
  • Failure modes: oncologic med; secondary malignancy risk; systemic derepression is not plate-targeted.
Azacitidine / Onureg (DNMT inhibitors)
  • Switch: DNA hypomethylation → very broad gene reactivation.
  • Theoretical upside: fetal/early growth program re-awakening (IGF2, etc.) in theory.
  • Failure modes: high-toxicity chemo; marrow suppression, infections; extreme dysmorph/tumor risk conceptually; no place in height.

Hair/skin & ancillary​

GHK-Cu
  • Switch: wound-healing/ECM signaling peptide.
  • Theoretical upside: local skin/ECM quality; no plate effect.
  • Failure modes: cosmetic gains only; no height role.
Finasteride/Dutasteride; RU58841
  • Switch: 5-ARI systemic (fin/dut); topical AR antagonist (RU; research chem).
  • Theoretical upside: mitigate DHT hair/skin effects during androgen use.
  • Failure modes: sexual/psych sides (5-ARIs); RU systemic absorption unknown.
AIs (class, again)
  • See above—blunt E2, risk bone/CNS; theoretical delay of fusion at real costs.
ARBs (Losartan/Telmisartan)
  • Switch: BP control; some PPAR-γ/anti-fibrotic (telmisartan).
  • Theoretical upside: safer hemodynamics on androgens; minor ECM tone effects.
  • Failure modes: hypotension, renal K+ issues.

Gonadotropins​

hCG / hMG
  • Switch: mimic LH (±FSH with hMG) → support testicular steroidogenesis/spermatogenesis.
  • Theoretical upside: preserve fertility axis during exogenous androgens.
  • Failure modes: E2 rises via intratesticular aromatase; gynecomastia risk; not a height lever.

“Gene PCT” supplements (SAMe, methyl-B12, methyl-folate, choline, creatine)​

  • Switch: methyl-donor pool, one-carbon metabolism, ATP buffering.
  • Theoretical upside: general metabolic support; no meaningful “close the genes” effect at the growth-plate level.
  • Failure modes: minimal if dosed sanely; don’t expect epigenetic reversals.

Net theoretical takeaways​

  • Length is a chondrocyte-cycle problem (IGF-1/Ihh–PTHrP/CNP vs ERα clock). Most agents above are bone mass/width levers or systemic sledgehammers.
  • The only pathway with clean, plate-centric pro-length logic in humans so far is CNP/NPR2 biasing vs FGFR3, and even that’s diagnosis-bound.
  • Systemic WNT, epigenetic drugs, pan-FGFR TKIs, non-aromatizing AAS: big, non-selective risks with no human height evidence.
  • AI-heavy strategies trade a possible delay in fusion for bone/CNS harm and still don’t guarantee added length.
If you want, I’ll condense this into a one-page matrix (Drug/Class → Primary switch → Plausible effect on length/width → Key failure mode → Evidence level) so you can scan it at a glance.
ignore that reply, i tweaked my prompt and ai just did a whole day of research in one fucking minute. look at this fact check












Short answer: the “OGRE gene drugs” write-up is mostly wrong or wildly over-interpreted. Here’s a clean fact-check on the biggest claims.


What these drugs actually are​


  • Vorinostat (Zolinza) is a pan-HDAC inhibitor approved for cutaneous T-cell lymphoma (CTCL). It changes histone acetylation and selectively alters transcription; it doesn’t “universally unlock genes.” Notable risks include thrombocytopenia, anemia, GI effects, DVT/PE. (FDA Access Data)
  • Tazmetostat (Tazverik) is a selective EZH2 inhibitor (PRC2/H3K27me3 pathway) approved for epithelioid sarcoma and certain follicular lymphomas. It carries warnings for secondary malignancies and embryo-fetal toxicity. (FDA Access Data)
  • Azacitidine is a DNMT inhibitor (“hypomethylating agent”)—Vidaza (injectable) for MDS and Onureg (oral azacitidine) for AML maintenance. Both are oncology drugs with substantial myelosuppression and other toxicities. (FDA Access Data)

All three are prescription anticancer agents—not “open-market” wellness enhancers.

Claim-by-claim​


“Vorinostat indiscriminately enhances gene expression and is good to ‘pair with androgens’ to boost masculinization.” — Incorrect.
HDAC inhibitors do not globally turn everything up; they modulate a subset of genes in a context-dependent way. In prostate models, vorinostat actually represses androgen receptor (AR) expression and shows synergy with AR antagonists, not with androgens. That’s the opposite of “amplifying androgen effects.” (PubMed)


“Vorinostat is bad for bones, but you can outpace that with ‘gear.’” — Misleading.
Multiple mouse studies show vorinostat can cause bone loss, largely by reducing osteoblast number; some in-vitro data are mixed and regimen-dependent, but this is not a benign effect you can assume away. (PMC)


“Tazmetostat removes the epigenetic brake on growth/puberty—turn on ‘second puberty’ with androgens.” — Wrong and unsafe.
EZH2/PRC2 isn’t a generic “puberty brake.” In the skeleton, EZH2 activity is required for normal chondrocyte proliferation and skeletal growth; loss of Ezh1/2 in chondrocytes impairs growth. Systemic EZH2 inhibition is not a tool to extend growth-plate activity or masculinization, and Tazmetostat specifically increases risk of secondary malignancies. (PMC)
(Separately, epigenetic regulation does influence hypothalamic puberty timing in rodents, but that doesn’t translate to “take an EZH2 inhibitor for height or a second puberty.”) (PMC)


“DNMT inhibitors (azacitidine/Onureg) re-activate pre-pubertal programs like fetal IGF2; effects are permanent.” — Misstated.
DNMT inhibitors cause global, replication-linked hypomethylation and re-expression of many silenced genes, mainly used to treat myeloid cancers. The hypomethylation is generally reversible after stopping (remethylation resumes), and it is not selective for “pubertal” genes. IGF2 does not “shut off forever after puberty” in humans. (BioMed Central)


“Tazmetostat is safer and just ‘re-exposes’ growth programs; Onureg is a stronger version.” — Misleading.
“Taz” is more selective than a pan-HDACi but not “safer” in healthy people (see secondary malignancy warning). “Stronger version” is inaccurate—azacitidine works via DNMT1 trapping/hypomethylation, a completely different mechanism from EZH2 inhibition. Both have serious hematologic risks and are meant for cancer care. (FDA Access Data)


“Make vorinostat bioavailable from raw powder / easy to source.” — No.
These are regulated oncology drugs that require medical supervision; compounding or sourcing advice isn’t appropriate, and self-experimentation is dangerous given the toxicity profiles above. (See labels.) (FDA Access Data)


“Gene PCT with SAMe, methyl-B12, folate, choline, creatine ‘closes genes’ after cycles.” — No evidence.
Dietary methyl donors can influence some DNA methylation marks in specific contexts, but there’s no clinical evidence that this “reverses” or safely counteracts the systemic hypomethylation or chromatin changes induced by DNMT/HDAC/EZH2 inhibitors. (PMC)


Bottom line​


  • These are powerful cancer drugs, not biohacking enhancers. The write-up’s central idea—that you can epigenetically flip on puberty/growth programs and stack with androgens—is unsupported and potentially harmful. (PMC)
  • If your interest is legitimate medical treatment (e.g., a cancer indication), talk to your oncologist. If the goal is physique/height/“second puberty,” there’s no evidence these agents are effective or safe for that use—and there’s clear evidence of serious risks. (FDA Access Data)

If you want, I can help you find evidence-based (and far safer) ways to preserve bone health or address hormone issues without venturing into oncology drugs.
 
  • +1
Reactions: PaulieGualtieri

Similar threads

7evenvox22
Replies
38
Views
2K
reazy
reazy
juanson
Replies
11
Views
513
ynns
Y
2 unknown slayer
Replies
7
Views
713
gigacumster3000
gigacumster3000

Users who are viewing this thread

  • keystrokes
Back
Top